AGN-151586
Phase 3Small molecule
AbbVieAGN-151586 is one of 3 small molecule programs targeting Moderate to Severe Glabellar Lines. It is currently in Phase 3.
2
Indications
8
Total Trials
0
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
4 competitors in Moderate to Severe Glabellar Lines
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Glabellar Lines6 trials
Show 3 more trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AGN-151586. EMBL-EBI & Wellcome Sanger Institute.
- [4]